Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strong topline growth driven by solid performance across key brands.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Subscribe To Our Newsletter & Stay Updated
